VBL Therapeutics to Establish New Mfg. Facility

VBL Therapeutics has entered a long-term lease contract for a new stand-alone facility in Modiin, Israel that will house its local biologics manufacturing facility, as the company plans for potential commercialization of Phase III oncology candidate, VB-111.
 
The site allows for modular expansion of manufacturing capacity to supply demand following commercialization, while requiring limited capital resources in the immediate stage. The company projects that its current cash will support operations into 2019, beyond the pivotal GLOBE trial, while supporting a potential registration trial in ovarian cancer and the investment in the new facility.
 
“Securing this new facility in Modiin fits strategically with our development plans and is an important step as we advance multiple clinical trials and move closer to potential commercialization of VB-111,” said Dror Harats, chief executive officer of VBL Therapeutics.
 
The new facility will also include the company’s headquarters, discovery research and clinical development. VBL intends to operate and relocate to the new site in 2H17.
 
VBL anticipates that future commercial supply of VB-111 will likely involve a complementary source of supply via a contract manufacturing partner in North America, although plans have not yet been made.